21 related articles for article (PubMed ID: 29155521)
1. Correlation of Neuroendocrine Differentiation with a Distinctively Suppressive Immune Microenvironment in Gastric Cancer.
Zou Y; Li D; Yu X; Zhou C; Zhu C; Yuan Y
Neuroendocrinology; 2024; 114(2):192-206. PubMed ID: 37827134
[TBL] [Abstract][Full Text] [Related]
2. Clinicopathological Features and Postoperative Survival Analysis of Gastric Carcinoma with Neuroendocrine Differentiation.
Liu J; Pan X; Sun Y; Dong T; Hu X; Zhong H; Lu J
J Oncol; 2022; 2022():4440098. PubMed ID: 36035314
[TBL] [Abstract][Full Text] [Related]
3. Clinicopathological Characteristics and Prognostic Factors of Patients with Gastric Cancer Accompanying Neuroendocrine Differentiation (NEDGC).
Wang YP; Hong J; Wang J; Bei YB; Hao HK; Hua LC
Cancer Manag Res; 2020; 12():4217-4225. PubMed ID: 32581593
[TBL] [Abstract][Full Text] [Related]
4. Docetaxel and Cisplatin Plus Fluorouracil compared with Modified Docetaxel, Cisplatin, and 5-Fluorouracil as first-line therapy for advanced gastric cancer: a retrospective analysis of single institution.
Inal A; Kaplan MA; Kucukoner M; Isikdogan A
Neoplasma; 2012; 59(2):233-6. PubMed ID: 22248282
[TBL] [Abstract][Full Text] [Related]
5. Randomized multicenter phase III study of a modified docetaxel and cisplatin plus fluorouracil regimen compared with cisplatin and fluorouracil as first-line therapy for advanced or locally recurrent gastric cancer.
Wang J; Xu R; Li J; Bai Y; Liu T; Jiao S; Dai G; Xu J; Liu Y; Fan N; Shu Y; Ba Y; Ma D; Qin S; Zheng L; Chen W; Shen L
Gastric Cancer; 2016 Jan; 19(1):234-44. PubMed ID: 25604851
[TBL] [Abstract][Full Text] [Related]
6. Randomized Multicenter Phase II Study of Modified Docetaxel, Cisplatin, and Fluorouracil (DCF) Versus DCF Plus Growth Factor Support in Patients With Metastatic Gastric Adenocarcinoma: A Study of the US Gastric Cancer Consortium.
Shah MA; Janjigian YY; Stoller R; Shibata S; Kemeny M; Krishnamurthi S; Su YB; Ocean A; Capanu M; Mehrotra B; Ritch P; Henderson C; Kelsen DP
J Clin Oncol; 2015 Nov; 33(33):3874-9. PubMed ID: 26438119
[TBL] [Abstract][Full Text] [Related]
7. The efficacy of modified docetaxel-cisplatin-5-fluorouracil regimen as first-line treatment in patients with alpha-fetoprotein producing gastric carcinoma.
Bozkaya Y; Doğan M; Yazıcı O; Erdem GU; Demirci NS; Zengin N
Bosn J Basic Med Sci; 2017 May; 17(2):138-143. PubMed ID: 28273032
[TBL] [Abstract][Full Text] [Related]
8. Outcome of FOLFOX and Modified DCF Chemotherapy Regimen in Patients with Advanced Gastric Adenocarcinoma.
Pourghasemian M; Danandeh Mehr A; Molaei M; Habibzadeh A
Asian Pac J Cancer Prev; 2020 Aug; 21(8):2337-2341. PubMed ID: 32856863
[TBL] [Abstract][Full Text] [Related]
9. Modified schedules of DCF chemotherapy for advanced gastric cancer: a systematic review of efficacy and toxicity.
Petrelli F; Tomasello G; Ghidini M; Passalacqua R; Barni S
Anticancer Drugs; 2017 Feb; 28(2):133-141. PubMed ID: 27749286
[TBL] [Abstract][Full Text] [Related]
10. A gastric neuroendocrine carcinoma with good prognosis after chemotherapy combined with immunotherapy: A case report (CARE-compliant).
Zhao Y; Yang R; Lu H
Medicine (Baltimore); 2023 Dec; 102(50):e36568. PubMed ID: 38115336
[TBL] [Abstract][Full Text] [Related]
11. Gastric adenocarcinoma with neuroendocrine differentiation: Clinicopathological features and efficacy of modified DCF chemotherapy.
Bozkaya Y; Ozdemir N; Colak A; Zengin N
J BUON; 2017; 22(4):919-925. PubMed ID: 29155521
[TBL] [Abstract][Full Text] [Related]
12.
; ; . PubMed ID:
[No Abstract] [Full Text] [Related]
13.
; ; . PubMed ID:
[No Abstract] [Full Text] [Related]
14.
; ; . PubMed ID:
[No Abstract] [Full Text] [Related]
15.
; ; . PubMed ID:
[No Abstract] [Full Text] [Related]
16.
; ; . PubMed ID:
[No Abstract] [Full Text] [Related]
17.
; ; . PubMed ID:
[No Abstract] [Full Text] [Related]
18.
; ; . PubMed ID:
[No Abstract] [Full Text] [Related]
19.
; ; . PubMed ID:
[No Abstract] [Full Text] [Related]
20.
; ; . PubMed ID:
[No Abstract] [Full Text] [Related]
[Next] [New Search]
